{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:15:22Z","timestamp":1788480922665,"version":"build-2803163510"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007165","name":"University of Missouri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01541-8","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:07:23Z","timestamp":1780506443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolving landscape of targeted immunotherapeutic interventions and CAR-T therapy for acute myeloid leukemia"],"prefix":"10.1038","volume":"10","author":[{"given":"Tara Chand","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanid","family":"Mohiyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard C.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senthilnathan","family":"Palaniyandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"1541_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal, S. & Sekeres, M. A. Contemporary management of acute myeloid leukemia: a review. JAMA Oncol. 10, 1417\u20131425 (2024).","journal-title":"JAMA Oncol."},{"key":"1541_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000536152","volume":"147","author":"F Wachter","year":"2024","unstructured":"Wachter, F. & Pikman, Y. Pathophysiology of acute myeloid leukemia. Acta Haematol. 147, 229\u2013246 (2024).","journal-title":"Acta Haematol."},{"key":"1541_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1328858","volume":"15","author":"K Maurer","year":"2024","unstructured":"Maurer, K. & Antin, J. H. The graft versus leukemia effect: donor lymphocyte infusions and cellular therapy. Front. Immunol. 15, 1328858 (2024).","journal-title":"Front. Immunol."},{"key":"1541_CR4","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41571-020-0356-4","volume":"17","author":"BR Blazar","year":"2020","unstructured":"Blazar, B. R., Hill, G. R. & Murphy, W. J. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nat. Rev. Clin. Oncol. 17, 475\u2013492 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1541_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2025.102526","volume":"82","author":"B Wang","year":"2025","unstructured":"Wang, B., Reville, P. K. & Abbas, H. A. Therapeutic hurdles in acute myeloid leukemia: Leukemic stem cells, inflammation and immune dysfunction. Curr. Opin. Pharm. 82, 102526 (2025).","journal-title":"Curr. Opin. Pharm."},{"key":"1541_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100146","volume":"2","author":"A Worker","year":"2025","unstructured":"Worker, A., Jinks, N., Woodmancy, P., Seedhouse, C. & Kellaway, S. G. How to drug a leukemic stem cell: deciphering heterogeneity for better specificity. Blood Neoplasia 2, 100146 (2025).","journal-title":"Blood Neoplasia"},{"key":"1541_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105090","volume":"218","author":"S Barachini","year":"2026","unstructured":"Barachini, S. et al. The role of the bone marrow microenvironment in leukemic stem cell resistance: Pathways of persistence and selection. Crit. Rev. Oncol. Hematol. 218, 105090 (2026).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1541_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00277-026-06742-6","volume":"105","author":"X Zhao","year":"2026","unstructured":"Zhao, X., Ming, X., Wu, J., Zhu, X. & Xiao, Y. Next-generation CAR-T therapy for acute myeloid leukemia: bridging innovation with clinical translation. Ann. Hematol. 105, 20 (2026).","journal-title":"Ann. Hematol."},{"key":"1541_CR9","doi-asserted-by":"publisher","unstructured":"Dunn, W. G., McLoughlin, M. A. & Vassiliou, G. S. Clonal hematopoiesis and hematological malignancy. J. Clin. Investig. 134. https:\/\/doi.org\/10.1172\/JCI180065 (2024).","DOI":"10.1172\/JCI180065"},{"key":"1541_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40164-020-00161-7","volume":"9","author":"J Yu","year":"2020","unstructured":"Yu, J., Li, Y., Zhang, D., Wan, D. & Jiang, Z. Clinical implications of recurrent gene mutations in acute myeloid leukemia. Exp. Hematol. Oncol. 9, 4 (2020).","journal-title":"Exp. Hematol. Oncol."},{"key":"1541_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.775128","volume":"12","author":"T Marchand","year":"2021","unstructured":"Marchand, T. & Pinho, S. Leukemic stem cells: from leukemic niche biology to treatment opportunities. Front Immunol. 12, 775128 (2021).","journal-title":"Front Immunol."},{"key":"1541_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.692800","volume":"9","author":"KE Miari","year":"2021","unstructured":"Miari, K. E., Guzman, M. L., Wheadon, H. & Williams, M. T. S. Macrophages in acute myeloid leukemia: significant players in therapy resistance and patient outcomes. Front Cell Dev. Biol. 9, 692800 (2021).","journal-title":"Front Cell Dev. Biol."},{"key":"1541_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P. & Trumpp, A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 108, 353\u2013366 (2023).","journal-title":"Haematologica"},{"key":"1541_CR14","doi-asserted-by":"publisher","unstructured":"Alsouqi, A., Geramita, E. & Im, A. Treatment of acute myeloid leukemia in older adults. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15225409 (2023).","DOI":"10.3390\/cancers15225409"},{"key":"1541_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e34951","volume":"10","author":"S Qian","year":"2024","unstructured":"Qian, S. et al. Targeted therapy for leukemia based on nanomaterials. Heliyon 10, e34951 (2024).","journal-title":"Heliyon"},{"key":"1541_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103710","volume":"175","author":"SK Khaldoyanidi","year":"2022","unstructured":"Khaldoyanidi, S. K., Hindoyan, A., Stein, A. & Subklewe, M. Leukemic stem cells as a target for eliminating acute myeloid leukemia: gaps in translational research. Crit. Rev. Oncol. Hematol. 175, 103710 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1541_CR17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41375-024-02191-0","volume":"38","author":"O Kovecses","year":"2024","unstructured":"Kovecses, O., Mercier, F. E. & McKeague, M. Nucleic acid therapeutics as differentiation agents for myeloid leukemias. Leukemia 38, 1441\u20131454 (2024).","journal-title":"Leukemia"},{"key":"1541_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-025-01764-2","volume":"25","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan, H. et al. Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. Clin. Exp. Med 25, 215 (2025).","journal-title":"Clin. Exp. Med"},{"key":"1541_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414264","volume":"15","author":"R Yang","year":"2024","unstructured":"Yang, R. et al. Advances in CAR-NK cell therapy for hematological malignancies. Front. Immunol. 15, 1414264 (2024).","journal-title":"Front. Immunol."},{"key":"1541_CR20","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10238-025-01686-z","volume":"25","author":"AK Bishoyi","year":"2025","unstructured":"Bishoyi, A. K. et al. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation. Clin. Exp. Med. 25, 166 (2025).","journal-title":"Clin. Exp. Med."},{"key":"1541_CR21","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41375-021-01432-w","volume":"36","author":"DT Johnson","year":"2022","unstructured":"Johnson, D. T. et al. Acute myeloid leukemia cell membrane-coated nanoparticles for cancer vaccination immunotherapy. Leukemia 36, 994\u20131005 (2022).","journal-title":"Leukemia"},{"key":"1541_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-021-00233-2","volume":"10","author":"Y Yao","year":"2021","unstructured":"Yao, Y., Li, F., Huang, J., Jin, J. & Wang, H. Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development. Exp. Hematol. Oncol. 10, 39 (2021).","journal-title":"Exp. Hematol. Oncol."},{"key":"1541_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000168","volume":"3","author":"N Bizymi","year":"2019","unstructured":"Bizymi, N. et al. Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets. Hemasphere 3, e168 (2019).","journal-title":"Hemasphere"},{"key":"1541_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108114","volume":"235","author":"S Joshi","year":"2022","unstructured":"Joshi, S. & Sharabi, A. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy. Pharm. Ther. 235, 108114 (2022).","journal-title":"Pharm. Ther."},{"key":"1541_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1158\/2643-3230.BCD-24-0063","volume":"6","author":"N Ho","year":"2025","unstructured":"Ho, N., Talvard-Balland, N., Kohler, N. & Zeiser, R. Immune escape of acute myeloid leukemia after transplantation. Blood Cancer Discov. 6, 168\u2013181 (2025).","journal-title":"Blood Cancer Discov."},{"key":"1541_CR26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"F Castro","year":"2018","unstructured":"Castro, F., Cardoso, A. P., Goncalves, R. M., Serre, K. & Oliveira, M. J. Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front. Immunol. 9, 847 (2018).","journal-title":"Front. Immunol."},{"key":"1541_CR27","doi-asserted-by":"publisher","unstructured":"Bolkun, L. et al. The association between immune checkpoint proteins and therapy outcomes in acute myeloid leukemia patients. Cancers 15. https:\/\/doi.org\/10.3390\/cancers15184487 (2023).","DOI":"10.3390\/cancers15184487"},{"key":"1541_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.764698","volume":"9","author":"DB Pimenta","year":"2021","unstructured":"Pimenta, D. B. et al. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Front. Cell Dev. Biol. 9, 764698 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1541_CR29","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1007\/s00277-025-06387-x","volume":"104","author":"OS Aval","year":"2025","unstructured":"Aval, O. S. et al. Galectin-9: a double-edged sword in acute myeloid leukemia. Ann. Hematol. 104, 3077\u20133090 (2025).","journal-title":"Ann. Hematol."},{"key":"1541_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00432-025-06244-4","volume":"151","author":"MJ Saadh","year":"2025","unstructured":"Saadh, M. J. et al. Mesenchymal stem cells in the bone marrow microenvironment: a double-edged sword for AML. J. Cancer Res. Clin. Oncol. 151, 193 (2025).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1541_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.896426","volume":"12","author":"J Niu","year":"2022","unstructured":"Niu, J., Peng, D. & Liu, L. Drug resistance mechanisms of acute myeloid leukemia stem cells. Front. Oncol. 12, 896426 (2022).","journal-title":"Front. Oncol."},{"key":"1541_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14590-9","volume":"11","author":"Y Sheng","year":"2020","unstructured":"Sheng, Y. et al. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Nat. Commun. 11, 928 (2020).","journal-title":"Nat. Commun."},{"key":"1541_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.ccell.2016.03.015","volume":"29","author":"ER Lechman","year":"2016","unstructured":"Lechman, E. R. et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell 29, 602\u2013606 (2016).","journal-title":"Cancer Cell"},{"key":"1541_CR34","doi-asserted-by":"publisher","unstructured":"Cao, S., Wang, Q. & Zhu, G. From chemotherapy to targeted therapy: unraveling resistance in acute myeloid leukemia through genetic and non-genetic insights. Int. J. Mol. Sci. 26. https:\/\/doi.org\/10.3390\/ijms26094005 (2025).","DOI":"10.3390\/ijms26094005"},{"key":"1541_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exphem.2022.04.001","volume":"111","author":"EM Kropp","year":"2022","unstructured":"Kropp, E. M. & Li, Q. Mechanisms of resistance to targeted therapies for relapsed or refractory acute myeloid leukemia. Exp. Hematol. 111, 13\u201324 (2022).","journal-title":"Exp. Hematol."},{"key":"1541_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/BS9.0000000000000020","volume":"1","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Molecular mechanisms for stemness maintenance of acute myeloid leukemia stem cells. Blood Sci. 1, 77\u201383 (2019).","journal-title":"Blood Sci."},{"key":"1541_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal, S. et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271\u2013285 (2009).","journal-title":"Cell"},{"key":"1541_CR38","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00277-025-06401-2","volume":"104","author":"V Sammartano","year":"2025","unstructured":"Sammartano, V. et al. Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia. Ann. Hematol. 104, 2737\u20132743 (2025).","journal-title":"Ann. Hematol."},{"key":"1541_CR39","doi-asserted-by":"publisher","unstructured":"Herbrich, S. et al. Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML. J. Immunother. Cancer 9 https:\/\/doi.org\/10.1136\/jitc-2021-002968 (2021).","DOI":"10.1136\/jitc-2021-002968"},{"key":"1541_CR40","doi-asserted-by":"publisher","unstructured":"Huang, Y., Wang, H. C., Zhao, J., Wu, M. H. & Shih, T. C. Immunosuppressive roles of galectin-1 in the tumor microenvironment. Biomolecules 11 https:\/\/doi.org\/10.3390\/biom11101398 (2021).","DOI":"10.3390\/biom11101398"},{"key":"1541_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41375-021-01350-x","volume":"36","author":"S Tettamanti","year":"2022","unstructured":"Tettamanti, S., Pievani, A., Biondi, A., Dotti, G. & Serafini, M. Catch me if you can: how AML and its niche escape immunotherapy. Leukemia 36, 13\u201322 (2022).","journal-title":"Leukemia"},{"key":"1541_CR42","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825\u20131863 (2024).","journal-title":"Cancer Cell"},{"key":"1541_CR43","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10238-025-01559-5","volume":"25","author":"M Rady","year":"2025","unstructured":"Rady, M. et al. Adoptive NK cell therapy in AML: progress and challenges. Clin. Exp. Med. 25, 41 (2025).","journal-title":"Clin. Exp. Med."},{"key":"1541_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01282-2","volume":"21","author":"M Bakhtiyari","year":"2023","unstructured":"Bakhtiyari, M. et al. The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. Cell Commun. Signal 21, 252 (2023).","journal-title":"Cell Commun. Signal"},{"key":"1541_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15817-5","volume":"11","author":"V Barbier","year":"2020","unstructured":"Barbier, V. et al. Endothelial E-selectin inhibition improves acute myeloid leukemia therapy by disrupting vascular niche-mediated chemoresistance. Nat. Commun. 11, 2042 (2020).","journal-title":"Nat. Commun."},{"key":"1541_CR46","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1084\/jem.20110132","volume":"208","author":"A Ehninger","year":"2011","unstructured":"Ehninger, A. & Trumpp, A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J. Exp. Med. 208, 421\u2013428 (2011).","journal-title":"J. Exp. Med."},{"key":"1541_CR47","doi-asserted-by":"publisher","unstructured":"Mesaros, O. et al. Macrophages as potential therapeutic targets in acute myeloid leukemia. Biomedicines 12. https:\/\/doi.org\/10.3390\/biomedicines12102306 (2024).","DOI":"10.3390\/biomedicines12102306"},{"key":"1541_CR48","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.3389\/fimmu.2018.02650","volume":"9","author":"K Cui","year":"2018","unstructured":"Cui, K., Ardell, C. L., Podolnikova, N. P. & Yakubenko, V. P. Distinct migratory properties of M1, M2, and resident macrophages are regulated by alpha(D)beta(2) and alpha(M)beta(2) integrin-mediated adhesion. Front. Immunol. 9, 2650 (2018).","journal-title":"Front. Immunol."},{"key":"1541_CR49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bph.16149","volume":"181","author":"HA Ogana","year":"2024","unstructured":"Ogana, H. A. et al. Targeting integrins in drug-resistant acute myeloid leukemia. Br. J. Pharm. 181, 295\u2013316 (2024).","journal-title":"Br. J. Pharm."},{"key":"1541_CR50","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5530650","volume":"2021","author":"F Magalhaes-Gama","year":"2021","unstructured":"Magalhaes-Gama, F. et al. Imbalance of chemokines and cytokines in the bone marrow microenvironment of children with B-cell acute lymphoblastic leukemia. J. Oncol. 2021, 5530650 (2021).","journal-title":"J. Oncol."},{"key":"1541_CR51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J. Exp. Clin. Cancer Res. 44, 145 (2025).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1541_CR52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1182\/blood-2009-12-258186","volume":"117","author":"L Sanchez-Martin","year":"2011","unstructured":"Sanchez-Martin, L. et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117, 88\u201397 (2011).","journal-title":"Blood"},{"key":"1541_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-024-01559-0","volume":"17","author":"B Toledo","year":"2024","unstructured":"Toledo, B. et al. Deciphering the performance of macrophages in tumor microenvironment: a call for precision immunotherapy. J. Hematol. Oncol. 17, 44 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1541_CR54","doi-asserted-by":"publisher","unstructured":"Moore, J. A. et al. LC3-associated phagocytosis in bone marrow macrophages suppresses acute myeloid leukemia progression through STING activation. J. Clin. Investig. 132. https:\/\/doi.org\/10.1172\/JCI153157 (2022).","DOI":"10.1172\/JCI153157"},{"key":"1541_CR55","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3324\/haematol.2018.197004","volume":"103","author":"PM Le","year":"2018","unstructured":"Le, P. M., Andreeff, M. & Battula, V. L. Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica 103, 1945\u20131955 (2018).","journal-title":"Haematologica"},{"key":"1541_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2023.101466","volume":"36","author":"G Magee","year":"2023","unstructured":"Magee, G. & Ragon, B. K. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Best. Pract. Res. Clin. Haematol. 36, 101466 (2023).","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"1541_CR57","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","volume":"118","author":"AK Burnett","year":"2002","unstructured":"Burnett, A. K. et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br. J. Haematol. 118, 385\u2013400 (2002).","journal-title":"Br. J. Haematol."},{"key":"1541_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01418-2","volume":"15","author":"S Elias","year":"2025","unstructured":"Elias, S. et al. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort. Blood Cancer J. 15, 208 (2025).","journal-title":"Blood Cancer J."},{"key":"1541_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.659595","volume":"12","author":"J Loke","year":"2021","unstructured":"Loke, J., Buka, R. & Craddock, C. Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how? Front. Immunol. 12, 659595 (2021).","journal-title":"Front. Immunol."},{"key":"1541_CR60","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.3389\/fonc.2019.01217","volume":"9","author":"C Sweeney","year":"2019","unstructured":"Sweeney, C. & Vyas, P. The graft-versus-leukemia effect in AML. Front. Oncol. 9, 1217 (2019).","journal-title":"Front. Oncol."},{"key":"1541_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01416-4","volume":"15","author":"B Salter","year":"2025","unstructured":"Salter, B. et al. Impact of expanding allogeneic stem cell transplantation on survival in acute myeloid leukemia: a population-based study. Blood Cancer J. 15, 204 (2025).","journal-title":"Blood Cancer J."},{"key":"1541_CR62","first-page":"794","volume":"30","author":"LM Morsink","year":"2024","unstructured":"Morsink, L. M. et al. Improved outcome of allogeneic transplantation in older patients treated for myeloid malignancies using post-transplantation cyclophosphamide and reduced duration of immune suppression. Transpl. Cell Ther. 30, 794\u2013807 (2024).","journal-title":"Transpl. Cell Ther."},{"key":"1541_CR63","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41375-025-02566-x","volume":"39","author":"C Reinhardt","year":"2025","unstructured":"Reinhardt, C. & Ochsenbein, A. F. Immune checkpoints regulate acute myeloid leukemia stem cells. Leukemia 39, 1277\u20131293 (2025).","journal-title":"Leukemia"},{"key":"1541_CR64","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-981-15-3266-5_9","volume":"1248","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. & Zheng, J. Functions of immune checkpoint molecules beyond immune evasion. Adv. Exp. Med. Biol. 1248, 201\u2013226 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"1541_CR65","doi-asserted-by":"publisher","unstructured":"Abaza, Y. & Zeidan, A. M. Immune checkpoint inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells 11. https:\/\/doi.org\/10.3390\/cells11142249 (2022).","DOI":"10.3390\/cells11142249"},{"key":"1541_CR66","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte, A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J. Exp. Clin. Cancer Res. 38, 255 (2019).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1541_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1056\/NEJMoa1601202","volume":"375","author":"MS Davids","year":"2016","unstructured":"Davids, M. S. et al. Ipilimumab for patients with relapse after allogeneic transplantation. N. Engl. J. Med. 375, 143\u2013153 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1541_CR68","doi-asserted-by":"publisher","unstructured":"Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6. https:\/\/doi.org\/10.1126\/sciadv.abd2712 (2020).","DOI":"10.1126\/sciadv.abd2712"},{"key":"1541_CR69","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-022-01328-x","volume":"15","author":"W Li","year":"2022","unstructured":"Li, W., Wang, F., Guo, R., Bian, Z. & Song, Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J. Hematol. Oncol. 15, 110 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"1541_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","volume":"11","author":"X Yang","year":"2022","unstructured":"Yang, X., Ma, L., Zhang, X., Huang, L. & Wei, J. Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp. Hematol. Oncol. 11, 11 (2022).","journal-title":"Exp. Hematol. Oncol."},{"key":"1541_CR71","doi-asserted-by":"publisher","unstructured":"Jimbu, L. et al. Is there a place for PD-1-PD-L blockade in acute myeloid leukemia? Pharmaceuticals 14. https:\/\/doi.org\/10.3390\/ph14040288 (2021).","DOI":"10.3390\/ph14040288"},{"key":"1541_CR72","doi-asserted-by":"publisher","unstructured":"Goswami, M. et al. Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia. J. Immunother. Cancer 10. https:\/\/doi.org\/10.1136\/jitc-2021-003392 (2022).","DOI":"10.1136\/jitc-2021-003392"},{"key":"1541_CR73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/1758834014567469","volume":"7","author":"DB Johnson","year":"2015","unstructured":"Johnson, D. B., Peng, C. & Sosman, J. A. Nivolumab in melanoma: latest evidence and clinical potential. Ther. Adv. Med. Oncol. 7, 97\u2013106 (2015).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1541_CR74","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1182\/bloodadvances.2022008403","volume":"7","author":"J Godfrey","year":"2023","unstructured":"Godfrey, J. et al. Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation. Blood Adv. 7, 963\u2013970 (2023).","journal-title":"Blood Adv."},{"key":"1541_CR75","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/cncr.34566","volume":"129","author":"Z Zeng","year":"2023","unstructured":"Zeng, Z. et al. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. Cancer 129, 531\u2013540 (2023).","journal-title":"Cancer"},{"key":"1541_CR76","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/cncr.33690","volume":"127","author":"K Saxena","year":"2021","unstructured":"Saxena, K. et al. A phase 1b\/2 study of azacitidine with PD-L1 antibody avelumab in relapsed\/refractory acute myeloid leukemia. Cancer 127, 3761\u20133771 (2021).","journal-title":"Cancer"},{"key":"1541_CR77","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","volume":"6","author":"AM Zeidan","year":"2022","unstructured":"Zeidan, A. M. et al. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML. Blood Adv. 6, 2219\u20132229 (2022).","journal-title":"Blood Adv."},{"key":"1541_CR78","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1182\/blood-2021-146039","volume":"138","author":"AM Brunner","year":"2021","unstructured":"Brunner, A. M. et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high\/high-risk myelodysplastic syndrome (vHR\/HR-MDS) and acute myeloid leukemia (AML): final analysis from a phase Ib study. Blood 138, 244\u2013244 (2021).","journal-title":"Blood"},{"key":"1541_CR79","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1158\/1078-0432.CCR-20-4746","volume":"27","author":"G Curigliano","year":"2021","unstructured":"Curigliano, G. et al. Phase I\/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin. Cancer Res. 27, 3620\u20133629 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1541_CR80","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","volume":"101","author":"AM Zeidan","year":"2022","unstructured":"Zeidan, A. M. et al. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann. Hematol. 101, 557\u2013569 (2022).","journal-title":"Ann. Hematol."},{"key":"1541_CR81","doi-asserted-by":"publisher","unstructured":"Hussein, B. A. et al. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells. J. Immunother. Cancer 11. https:\/\/doi.org\/10.1136\/jitc-2023-007202 (2023).","DOI":"10.1136\/jitc-2023-007202"},{"key":"1541_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03869-w","volume":"25","author":"A Dozandeh-Jouybari","year":"2025","unstructured":"Dozandeh-Jouybari, A. et al. One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors. Cancer Cell Int 25, 254 (2025).","journal-title":"Cancer Cell Int"},{"key":"1541_CR83","doi-asserted-by":"publisher","unstructured":"Damiani, D. & Tiribelli, M. Monoclonal antibodies against myeloid leukemia cells: current knowledge and future directions. Int. J. Mol. Sci. 26. https:\/\/doi.org\/10.3390\/ijms26104571 (2025).","DOI":"10.3390\/ijms26104571"},{"key":"1541_CR84","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-020-0910-8","volume":"26","author":"C Riether","year":"2020","unstructured":"Riether, C. et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat. Med. 26, 1459\u20131467 (2020).","journal-title":"Nat. Med."},{"key":"1541_CR85","doi-asserted-by":"publisher","unstructured":"Allen, C., Zeidan, A. M. & Bewersdorf, J. P. BiTEs, DARTS, BiKEs and TriKEs-are antibody based therapies changing the future treatment of AML? Life 11. https:\/\/doi.org\/10.3390\/life11060465 (2021).","DOI":"10.3390\/life11060465"},{"key":"1541_CR86","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood-2023-187721","volume":"142","author":"GS Guru Murthy","year":"2023","unstructured":"Guru Murthy, G. S. et al. A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed\/refractory acute myeloid leukemia. Blood 142, 1541\u20131541 (2023).","journal-title":"Blood"},{"key":"1541_CR87","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/10428194.2024.2346755","volume":"65","author":"F Ravandi","year":"2024","unstructured":"Ravandi, F. et al. Safety and tolerability of AMG 330 in adults with relapsed\/refractory AML: a phase 1a dose-escalation study. Leuk. Lymphoma 65, 1281\u20131291 (2024).","journal-title":"Leuk. Lymphoma"},{"key":"1541_CR88","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","volume":"7","author":"F Ravandi","year":"2023","unstructured":"Ravandi, F. et al. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia. Blood Adv. 7, 6492\u20136505 (2023).","journal-title":"Blood Adv."},{"key":"1541_CR89","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/imm.13636","volume":"169","author":"Y Yao","year":"2023","unstructured":"Yao, Y., Hu, Y. & Wang, F. Trispecific antibodies for cancer immunotherapy. Immunology 169, 389\u2013399 (2023).","journal-title":"Immunology"},{"key":"1541_CR90","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1365-2141.2010.08300.x","volume":"150","author":"M Kugler","year":"2010","unstructured":"Kugler, M. et al. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukemia cells by dual targeting. Br. J. Haematol. 150, 574\u2013586 (2010).","journal-title":"Br. J. Haematol."},{"key":"1541_CR91","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","volume":"11","author":"MK Gleason","year":"2012","unstructured":"Gleason, M. K. et al. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol. Cancer Ther. 11, 2674\u20132684 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"1541_CR92","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1182\/blood-2023-184797","volume":"142","author":"A Zabaleta","year":"2023","unstructured":"Zabaleta, A. et al. A CD38\/CD28xCD3 trispecific T-cell engager (TCE) as a potentially active agent for the treatment of older patients with acute myeloid leukemia (AML). Blood 142, 4178\u20134178 (2023).","journal-title":"Blood"},{"key":"1541_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1274088","volume":"14","author":"F Riccardi","year":"2023","unstructured":"Riccardi, F., Dal Bo, M., Macor, P. & Toffoli, G. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy. Front. Pharm. 14, 1274088 (2023).","journal-title":"Front. Pharm."},{"key":"1541_CR94","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct. Target Ther. 7, 93 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"1541_CR95","doi-asserted-by":"publisher","unstructured":"Pettinato, M. C. Introduction to antibody-drug conjugates. Antibodies 10. https:\/\/doi.org\/10.3390\/antib10040042 (2021).","DOI":"10.3390\/antib10040042"},{"key":"1541_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.2","volume":"7","author":"SS Hoseini","year":"2017","unstructured":"Hoseini, S. S. & Cheung, N. K. Acute myeloid leukemia targets for bispecific antibodies. Blood Cancer J. 7, e522 (2017).","journal-title":"Blood Cancer J."},{"key":"1541_CR97","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1021\/acsmedchemlett.0c00325","volume":"11","author":"YB Poudel","year":"2020","unstructured":"Poudel, Y. B. et al. Chemical modification of linkers provides stable linker-payloads for the generation of antibody-drug conjugates. ACS Med. Chem. Lett. 11, 2190\u20132194 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"1541_CR98","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang, R. et al. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals. J. Hematol. Oncol. 18, 51 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"1541_CR99","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2551205","volume":"17","author":"HBS Griffiths","year":"2025","unstructured":"Griffiths, H. B. S. et al. A bispecific antibody-drug conjugate targeting CD7 and CD33 shows anti-tumor activity and improved tumor selectivity in an aggressive subtype of acute myeloid leukemia. MAbs 17, 2551205 (2025).","journal-title":"MAbs"},{"key":"1541_CR100","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","volume":"130","author":"FR Appelbaum","year":"2017","unstructured":"Appelbaum, F. R. & Bernstein, I. D. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood 130, 2373\u20132376 (2017).","journal-title":"Blood"},{"key":"1541_CR101","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1158\/1538-7445.AM2024-3139","volume":"84","author":"W Wan","year":"2024","unstructured":"Wan, W. et al. Abstract 3139: BL-M11D1, a novel CD33-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation. Cancer Res. 84, 3139\u20133139 (2024).","journal-title":"Cancer Res."},{"key":"1541_CR102","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41375-024-02510-5","volume":"39","author":"M Able","year":"2025","unstructured":"Able, M. et al. Effective eradication of acute myeloid leukemia stem cells with FLT3-directed antibody-drug conjugates. Leukemia 39, 632\u2013642 (2025).","journal-title":"Leukemia"},{"key":"1541_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan, H. et al. Unveiling the potential of CLL-1: a promising target for AML therapy. Biomark. Res. 13, 28 (2025).","journal-title":"Biomark. Res."},{"key":"1541_CR104","first-page":"33","volume":"1","author":"Y Fu","year":"2018","unstructured":"Fu, Y. & Ho, M. DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antib. Ther. 1, 33\u201343 (2018).","journal-title":"Antib. Ther."},{"key":"1541_CR105","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13045-023-01523-4","volume":"17","author":"K Gera","year":"2024","unstructured":"Gera, K. et al. Vaccines: a promising therapy for myelodysplastic syndrome. J. Hematol. Oncol. 17, 4 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"1541_CR106","doi-asserted-by":"publisher","unstructured":"Barbullushi, K. et al. Vaccination therapy for acute myeloid leukemia: where do we stand? Cancers 14. https:\/\/doi.org\/10.3390\/cancers14122994 (2022).","DOI":"10.3390\/cancers14122994"},{"key":"1541_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116132","volume":"171","author":"Y Wu","year":"2024","unstructured":"Wu, Y. et al. Immunotherapies of acute myeloid leukemia: rationale, clinical evidence and perspective. Biomed. Pharmacother. 171, 116132 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1541_CR108","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fimmu.2015.00036","volume":"6","author":"A Di Stasi","year":"2015","unstructured":"Di Stasi, A., Jimenez, A. M., Minagawa, K., Al-Obaidi, M. & Rezvani, K. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol. 6, 36 (2015).","journal-title":"Front Immunol."},{"key":"1541_CR109","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3324\/haematol.2009.014704","volume":"95","author":"J Greiner","year":"2010","unstructured":"Greiner, J. et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 95, 1191\u20131197 (2010).","journal-title":"Haematologica"},{"key":"1541_CR110","doi-asserted-by":"publisher","first-page":"1504.1501","DOI":"10.1182\/blood-2024-198082","volume":"144","author":"S Jung","year":"2024","unstructured":"Jung, S. et al. Trial in progress: phase I trial evaluating an immunopeptidome-defined multi-peptide vaccine against acute myeloid leukemia stem and progenitor cells. Blood 144, 1504.1501\u20131504.1501 (2024).","journal-title":"Blood"},{"key":"1541_CR111","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7\u201324 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1541_CR112","doi-asserted-by":"publisher","first-page":"647","DOI":"10.3109\/14653249.2012.693744","volume":"14","author":"S Anguille","year":"2012","unstructured":"Anguille, S., Willemen, Y., Lion, E., Smits, E. L. & Berneman, Z. N. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 14, 647\u2013656 (2012).","journal-title":"Cytotherapy"},{"key":"1541_CR113","doi-asserted-by":"publisher","unstructured":"Van Acker, H. H. et al. Dendritic cell-based immunotherapy of acute myeloid leukemia. J. Clin. Med. 8. https:\/\/doi.org\/10.3390\/jcm8050579 (2019).","DOI":"10.3390\/jcm8050579"},{"key":"1541_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108467","volume":"217","author":"C Ansprenger","year":"2020","unstructured":"Ansprenger, C., Amberger, D. C. & Schmetzer, H. M. Potential of immunotherapies in the mediation of antileukemic responses for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)\u2014with a focus on Dendritic cells of leukemic origin (DC(leu)). Clin. Immunol. 217, 108467 (2020).","journal-title":"Clin. Immunol."},{"key":"1541_CR115","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1458449","volume":"14","author":"S Jung","year":"2024","unstructured":"Jung, S. et al. AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients. Front. Oncol. 14, 1458449 (2024).","journal-title":"Front. Oncol."},{"key":"1541_CR116","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti, I. et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct. Target Ther. 10, 210 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"1541_CR117","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1541_CR118","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/imm.13462","volume":"166","author":"A Zarezadeh Mehrabadi","year":"2022","unstructured":"Zarezadeh Mehrabadi, A. et al. The roles of interleukin-1 receptor accessory protein in certain inflammatory conditions. Immunology 166, 38\u201346 (2022).","journal-title":"Immunology"},{"key":"1541_CR119","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.797440","volume":"10","author":"A Alnefaie","year":"2022","unstructured":"Alnefaie, A. et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions. Front. Bioeng. Biotechnol. 10, 797440 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"1541_CR120","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2378543","volume":"20","author":"D Goyco Vera","year":"2024","unstructured":"Goyco Vera, D., Waghela, H., Nuh, M., Pan, J. & Lulla, P. Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum. Vaccin. Immunother. 20, 2378543 (2024).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1541_CR121","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.ymthe.2025.03.052","volume":"33","author":"M Khalifeh","year":"2025","unstructured":"Khalifeh, M., Hopewell, E. & Salman, H. CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes. Mol. Ther. 33, 2441\u20132453 (2025).","journal-title":"Mol. Ther."},{"key":"1541_CR122","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13046-023-02841-8","volume":"42","author":"E Peroni","year":"2023","unstructured":"Peroni, E., Randi, M. L., Rosato, A. & Cagnin, S. Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment. J. Exp. Clin. Cancer Res. 42, 259 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1541_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546172","volume":"16","author":"S Gomez-Melero","year":"2025","unstructured":"Gomez-Melero, S. et al. Tandem CAR-T cell therapy: recent advances and current challenges. Front. Immunol. 16, 1546172 (2025).","journal-title":"Front. Immunol."},{"key":"1541_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin, H., Yang, X., Ye, S., Huang, L. & Mu, W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed. Pharmacother. 178, 117252 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1541_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej, K. M. et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22, 20 (2023).","journal-title":"Mol. Cancer"},{"key":"1541_CR126","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jconrel.2024.02.033","volume":"368","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Adoptive cell therapy for solid tumors beyond CAR-T: current challenges and emerging therapeutic advances. J. Control Release 368, 372\u2013396 (2024).","journal-title":"J. Control Release"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01541-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01541-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01541-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:02:40Z","timestamp":1788480160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01541-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01541-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.C.H. received preclinical research funding from Aceta Pharma and Incyte, and advisory roles in the field of GVHD with Incyte. Stocks from Pfizer, Kite Pharma, Incyte, Jazz Pharmaceuticals, Morphosys, Alexion Pharmaceuticals, Daichiy, Karyopharm Therapeutics, Seattle Genetics, Jannsen Pharmaceuticals, RAPA Therapeutics, Ono Pharmaceutical, AstraZeneca, and CTI BioPharma Corp. S.P. received preclinical research funding from Aceta Pharma and Incyte. Other authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"341"}}